• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

HIV-1蛋白酶突变I47A在临床实践中的流行情况及其与洛匹那韦耐药性的关联。

Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.

作者信息

de Mendoza Carmen, Valer Luisa, Bacheler Lee, Pattery Theresa, Corral Angélica, Soriano Vincent

机构信息

Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.

出版信息

AIDS. 2006 Apr 24;20(7):1071-4. doi: 10.1097/01.aids.0000222084.44411.cc.

DOI:10.1097/01.aids.0000222084.44411.cc
PMID:16603864
Abstract

Mutation proI47A has recently been associated with lopinavir/ritonavir (LPV/r) resistance. Only four out of 1859 specimens (0.2%) sent for drug resistance testing (219 drug-naive and 1650 antiretroviral-experienced) showed I47A. All belonged to patients failing LPV/r. The prevalence among protease inhibitor-experienced patients was 0.6%. Phenotypic testing showed that proI47A caused high-level lopinavir resistance (> 100-fold) and cross-resistance to amprenavir, whereas it caused hypersusceptibility to saquinavir. ProI47A should thus be considered the primary lopinavir resistance mutation.

摘要

I47A突变最近被认为与洛匹那韦/利托那韦（LPV/r）耐药有关。在送去进行耐药性检测的1859份样本（219份初治患者样本和1650份接受过抗逆转录病毒治疗患者样本）中，只有4份（0.2%）检测出I47A。所有这些样本均来自使用LPV/r治疗失败的患者。在接受过蛋白酶抑制剂治疗的患者中，该突变的发生率为0.6%。表型检测显示，I47A导致高水平的洛匹那韦耐药（>100倍）以及对安普那韦的交叉耐药，而对沙奎那韦敏感。因此，I47A应被视为主要的洛匹那韦耐药突变。

相似文献

1
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.HIV-1蛋白酶突变I47A在临床实践中的流行情况及其与洛匹那韦耐药性的关联。
AIDS. 2006 Apr 24;20(7):1071-4. doi: 10.1097/01.aids.0000222084.44411.cc.
2
The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.耐药性算法和基因型抑制商在预测曾接受过1型人类免疫缺陷病毒蛋白酶抑制剂治疗的患者中洛匹那韦-利托那韦治疗反应中的应用。
J Clin Virol. 2007 Feb;38(2):131-8. doi: 10.1016/j.jcv.2006.11.011. Epub 2007 Jan 4.
3
Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.在接受过蛋白酶抑制剂治疗、感染1型人类免疫缺陷病毒且基于洛匹那韦和利托那韦的治疗失败的受试者中耐药性的选择：突变模式及基线相关性
J Virol. 2005 Mar;79(6):3329-38. doi: 10.1128/JVI.79.6.3329-3338.2005.
4
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.对含蛋白酶抑制剂的高效抗逆转录病毒治疗方案治疗失败患者的临床分离株，洛匹那韦、福沙普那韦（无论是否联用利托那韦）的基因型耐药性：患病率及预测因素
Scand J Infect Dis. 2007;39(9):813-8. doi: 10.1080/00365540701367728.
5
Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.初治和经治患者中HIV-1蛋白酶密码子33突变及多态性的流行情况与影响
Antivir Ther. 2006;11(4):457-63.
6
Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.HIV-1蛋白酶基因型和虚拟表型对含洛匹那韦/利托那韦挽救治疗方案病毒学应答的预测价值
Antivir Ther. 2004 Aug;9(4):595-602.
7
Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.在基于奈非那韦和洛匹那韦/利托那韦的治疗出现病毒学失败后，HIV-1蛋白酶中的突变模式及相关氨基酸替换
J Med Virol. 2007 Nov;79(11):1617-28. doi: 10.1002/jmv.20986.
8
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.一项双盲研究中，比较洛匹那韦/利托那韦加司他夫定和拉米夫定与奈非那韦加司他夫定和拉米夫定的耐药发生率。
J Infect Dis. 2004 Jan 1;189(1):51-60. doi: 10.1086/380509. Epub 2003 Dec 31.
9
Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects.安普那韦和洛匹那韦基因型耐药谱的区分，对有蛋白酶抑制剂治疗史的HIV-1感染患者的治疗选择有重要帮助。
J Antimicrob Chemother. 2003 Sep;52(3):319-23. doi: 10.1093/jac/dkg392. Epub 2003 Aug 13.
10
Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.蛋白酶抑制剂经治患者对洛匹那韦-利托那韦病毒学应答的预测性基因算法
Antimicrob Agents Chemother. 2007 Sep;51(9):3067-74. doi: 10.1128/AAC.00388-07. Epub 2007 Jun 18.

引用本文的文献

1
Viral proteases as therapeutic targets.病毒蛋白酶作为治疗靶点。
Mol Aspects Med. 2022 Dec;88:101159. doi: 10.1016/j.mam.2022.101159. Epub 2022 Nov 29.
2
Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.用于监测传播耐药性的 HIV-1 突变的时间趋势。
Viruses. 2021 May 11;13(5):879. doi: 10.3390/v13050879.
3
The Geogenomic Mutational Atlas of Pathogens (GoMAP) web system.病原体地理基因组突变图谱（GoMAP）网络系统
PLoS One. 2014 Mar 27;9(3):e92877. doi: 10.1371/journal.pone.0092877. eCollection 2014.
4
Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.塞内加尔接受抗逆转录病毒治疗的 HIV-2 患者中蛋白酶抑制剂耐药的复杂模式：对二线治疗的影响。
Antimicrob Agents Chemother. 2013 Jun;57(6):2751-60. doi: 10.1128/AAC.00405-13. Epub 2013 Apr 9.
5
Current and Novel Inhibitors of HIV Protease.当前和新型 HIV 蛋白酶抑制剂。
Viruses. 2009 Dec;1(3):1209-39. doi: 10.3390/v1031209. Epub 2009 Dec 11.
6
The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?HIV-1 蛋白酶中的 L76V 突变可能与对蛋白酶抑制剂阿扎那韦和沙奎那韦的超敏性有关：是否有临床优势？
AIDS Res Ther. 2011 Feb 13;8:7. doi: 10.1186/1742-6405-8-7.
7
Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage.HIV-1 亚型 B 和 C 蛋白酶中的突变 T74S 使它们重新对利托那韦和茚地那韦敏感，并赋予其适应性优势。
J Antimicrob Chemother. 2009 Nov;64(5):938-44. doi: 10.1093/jac/dkp315. Epub 2009 Aug 26.
8
Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir.对导致对HIV蛋白酶抑制剂洛匹那韦敏感性降低的I47A突变进行的酶学和结构分析。
Protein Sci. 2008 Sep;17(9):1555-64. doi: 10.1110/ps.036079.108. Epub 2008 Jun 17.
9
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.对洛匹那韦敏感性降低的2型人类免疫缺陷病毒的体外筛选与特性研究
Antimicrob Agents Chemother. 2007 Sep;51(9):3075-80. doi: 10.1128/AAC.00146-07. Epub 2007 Jun 18.